Cargando…
Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799066/ https://www.ncbi.nlm.nih.gov/pubmed/35116975 http://dx.doi.org/10.21037/tcr.2019.08.18 |
| _version_ | 1784641978348077056 |
|---|---|
| author | Tanzawa, Shigeru Ishihara, Masashi Haruyama, Terunobu Ochiai, Ryosuke Sakamoto, Takahiko Honda, Takeshi Ota, Shuji Ichikawa, Yasuko Watanabe, Kiyotaka Seki, Nobuhiko |
| author_facet | Tanzawa, Shigeru Ishihara, Masashi Haruyama, Terunobu Ochiai, Ryosuke Sakamoto, Takahiko Honda, Takeshi Ota, Shuji Ichikawa, Yasuko Watanabe, Kiyotaka Seki, Nobuhiko |
| author_sort | Tanzawa, Shigeru |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8799066 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87990662022-02-02 Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR? Tanzawa, Shigeru Ishihara, Masashi Haruyama, Terunobu Ochiai, Ryosuke Sakamoto, Takahiko Honda, Takeshi Ota, Shuji Ichikawa, Yasuko Watanabe, Kiyotaka Seki, Nobuhiko Transl Cancer Res Editorial Commentary AME Publishing Company 2019-10 /pmc/articles/PMC8799066/ /pubmed/35116975 http://dx.doi.org/10.21037/tcr.2019.08.18 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Commentary Tanzawa, Shigeru Ishihara, Masashi Haruyama, Terunobu Ochiai, Ryosuke Sakamoto, Takahiko Honda, Takeshi Ota, Shuji Ichikawa, Yasuko Watanabe, Kiyotaka Seki, Nobuhiko Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR? |
| title | Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR? |
| title_full | Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR? |
| title_fullStr | Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR? |
| title_full_unstemmed | Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR? |
| title_short | Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR? |
| title_sort | which is better, egfr-tki mono or combination for non-small cell lung cancer with mutated egfr? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799066/ https://www.ncbi.nlm.nih.gov/pubmed/35116975 http://dx.doi.org/10.21037/tcr.2019.08.18 |
| work_keys_str_mv | AT tanzawashigeru whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT ishiharamasashi whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT haruyamaterunobu whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT ochiairyosuke whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT sakamototakahiko whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT hondatakeshi whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT otashuji whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT ichikawayasuko whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT watanabekiyotaka whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr AT sekinobuhiko whichisbetteregfrtkimonoorcombinationfornonsmallcelllungcancerwithmutatedegfr |